Insights into the redox cycle of human quinone reductase 2

Free Radical Research

Volumn 45, Issue 10, 2011, Pages 1184-1195

  Reybier, Karine ^a,b   Perio, Pierre ^a,b   Ferry, Gilles ^c   Bouajila, Jalloul ^a,b   Delagrange, Philippe ^c   Boutin, Jean A ^c   Nepveu, Françoise ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UMR 152 IRD Universite Paul Sabatier   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Electron paramagnetic resonance; Free radicals; Menadione; Quinone reductase 1; Quinone reductase 2; Reactive oxygen species

Indexed keywords

CATALASE; CELL ENZYME; DICOUMAROL; ENZYME INHIBITOR; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MELATONIN; MENADIONE; N BENZYLDIHYDRONICOTINAMIDE; NICOTINAMIDE DERIVATIVE; NICOTINAMIDE RIBOSIDE; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESVERATROL; S 29434; TRETAZICAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOOXIDATION; CATALYSIS; CHO CELL; CONTROLLED STUDY; DRUG BINDING; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; ENZYME SYNTHESIS; FENTON REACTION; HUMAN; NONHUMAN; OXIDATION REDUCTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BINDING SITES; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; FREE RADICALS; HUMANS; HYDROGEN PEROXIDE; MICE; OXIDATION-REDUCTION; PRODRUGS; QUINONE REDUCTASES; SUBSTRATE SPECIFICITY;

EID: 80052752146     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2011.605788     Document Type: Article

References (46)

1. Venugopal R, Joseph P, Jaiswal AK. Gene expression of DT-diaphorase in cancer cells. In: Henry JF, Enrique C (eds). Oxidative stress and signal transduction. New York: Chapman & Hall; 1997. pp. 441-475.
2. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 1995;82-83:173-179. (Pubitemid 26057505)
3. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharm 1992;43:1657-1669.
4. Long II DJ, Jaiswal AK. Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene-and tissue-specifi c expression. Gene 2000;252:107-117. (Pubitemid 30618817)
5. Kappus H, Sies H. Toxic drug effects associated with oxygen metabolism: redox cycling and lipid peroxidation. Experientia 1981;37:1233-1241. (Pubitemid 12168965)
6. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000; 13:135-160. (Pubitemid 30169958)
7. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D, NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77-97. (Pubitemid 32061055)
8. Shen J, Barrios RJ, Jaiswal AK. Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res 2010;70(3):1006-1014.
9. Ross D, Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115-144. (Pubitemid 38240788)
10. Nishiyama T, Izawa T, Usami M, Ohnuma T, Ogura K, Hiratsuka A. UDP-glucuronosyltransferases 1A6 and 1A10 catalyze reduced menadione glucuronidation. Biochem Biophys Res Commun 2010;394:459-463.
11. Chen S, Wu KB, Knox R. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med 2000;29:276-284.
12. Li R, Bianchet MA, Talalay P, Amzel LM. The threedimensional structure of NAD(P)H: quinone reductase, a fl avoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc Natl Acad Sci USA. 1995;92:8846-8850.
13. Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM. Crystal structure of human quinone reductase. Biochemistry 1999;38:9881-9886.
14. Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, et al. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997;347:221, 8.
15. Long II DJ, Iskander K, Gaikwad A, Arin M, Roop D, Knox R, et al. Disruption of NRH:quinone oxidoreductase2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002;277:46131-46139. (Pubitemid 35417602)
16. Vella F, Ferry G, Delagrange P, Boutin JA. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005;71:1-12. (Pubitemid 41715231)
17. Calamini B, Santarsiero BD, Boutin JA, Mesecar AD. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J 2008;413:81-91. (Pubitemid 351946864)
18. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004;43:11417-11426. (Pubitemid 39186963)
19. Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, et al. Old and new inhibitors of quinone reductase 2. Chem Biol Interact 2010 Jul 30;186:103-109.
20. Mailliet F, Ferry G, Vella F, Berger S, Cogé F, Chomarat P, et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol 2005;71:74-88. (Pubitemid 41713529)
21. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, et al. Identifi cation of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275: 31311-31317.
22. Boutin JA, Chatelain-Egger F, Vella F, Delagrange P, Ferry G. Quinone reductase 2 substrate specifi city and inhibition pharmacology. Chem Biol Interact 2005;151:213-228. (Pubitemid 40279065)
23. Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, et al. Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci Transl Med 2010;2:40-50.
24. Christofferson A, Wilkie J. Mechanism of CB1954 reduction by Escherichia coli nitroreductase. Biochem Soc Trans 2009; 37:413-418.
25. Qiu XB, Cadenas E. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells. Arch Biochem Biophys 1997;346: 241-251. (Pubitemid 27439042)
26. Nutter LM, Ngo E, Fisher GR, Gutierrez PL. DNA strand scission and free radical production in menadione-treated cells. Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase. J Biol Chem 1992;267: 2474-2479.
27. Zhao Q, Yang XL, Holtzclaw WD, Talalay P. Unexpected genetic and structural relationships of a long-forgotten fl avoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc Natl Acad Sci USA 1997;94:1669-1674. (Pubitemid 27113893)
28. Jaiswal AK. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991;30:10647-10653.
29. Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004;43(15):4538-4547. (Pubitemid 38500583)
30. Z hu BZ, Kalyanaraman B, Jiang GB. Molecular mechanism for metal-independent production of hydroxyl radicals by hydrogen peroxide and halogenated quinones. Proc Natl Acad Sci USA 2007;104(45):17575-17578. (Pubitemid 350210876)
31. Hasinoff BB, Begleiter A. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells. Free Radic Res 2006;40(9):974-978. (Pubitemid 44480561)
32. Cadenas E. Antioxidant and prooxydant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995;49:127-140.
33. Fridovich I. The biology of oxygen radicals. Science 1978; 201:875-880.
34. Pedersen JA. On the application of electron paramagnetic resonance in the study of naturally occurring quinones and quinols. Spectrochim Acta A Mol Biomol Spectrosc 2002; 58:1257-1270. (Pubitemid 34222664)
35. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev 2004;36:639-654. (Pubitemid 39453067)
36. Audi SH, Zhao H, Bongard RD, Hogg N, Kettenhofen NJ, Kalyanaraman B, et al. Pulmonary arterial endothelial cells affect the redox status of coenzyme Q0. Free Rad Biol Med 2003;34:892-907. (Pubitemid 36321821)
37. Linnane AW, Kios M, Vitetta L. Coenzyme Q(10)-its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion 2007;7 Suppl:S51-S56
38. King MS, Sharpley MS, Hirst J. Reduction of hydrophilic ubiquinones by the fl avin in tmitochondria NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species. Biochemistry 2009;48:2053-2062.
39. Celli CM, Tran N, Knox R, Jaiswal AK. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006; 72:366-376. (Pubitemid 43975085)
40. Jaiswal AK, Bell DW, Radjendirane V, Testa JR. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphisms. Pharmacogenetics 1999;9: 413-418. (Pubitemid 29376389)
41. Hosoda S, Nakamura W, Hayashi K. Properties and reaction mechanism of DT diaphorase from rat liver. J Biol Chem 1974; 249:6416-6423.
42. Maiti A, Reddy PV, Sturdy M, Marler L, Pegan SD, Mesecar AD, et al. Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem 2009;52:1873-1884.
43. Boutin, JA. Indirect evidences of UDP-glucuronosyltransferase heterogeneity: how can it help purifi cation? Drug Metab Rev 1987;18:517-551.
44. Ma Q, Lu AY. The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters. Curr Drug Metab 2008;9:374-383. (Pubitemid 352025192)
45. Benoit CE, Bastianetto S, Brouillette J, Tse YC, Boutin JA, Delagrange P, et al. Loss of quinone reductase 2 function selectively facilitates learning behaviours. J Neurosci 2010; 30:12690-12700.
46. Wang W, Jaiswal AK. Sp3 repression of polymorphic human NRH:quinone oxidoreductase 2 gene promoter. Free Radic Biol Med 2004;37:1231-1243. (Pubitemid 39296748)